Press Releases

October 12, 2021
Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit Read More
October 11, 2021
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program Read More
October 4, 2021
Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting Read More
September 17, 2021
Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program Read More
September 15, 2021
Protagonist Therapeutics Reports Granting of Inducement Awards Read More
September 7, 2021
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology Read More
August 10, 2021
Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma Read More
August 4, 2021
Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress Read More
July 28, 2021
Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists Read More
June 30, 2021
Protagonist Therapeutics Reports Granting of Inducement Award Read More
June 18, 2021
Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Read More
June 15, 2021
Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock Read More
June 14, 2021
Protagonist Therapeutics Announces Proposed Public Offering of Common Stock Read More
June 11, 2021
Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera Read More
June 7, 2021
Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021 Read More
June 3, 2021
Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera Read More
May 24, 2021
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232 Read More
May 12, 2021
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Read More
May 4, 2021
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update Read More
May 3, 2021
Protagonist Therapeutics Reports Granting of Inducement Award Read More